Schedule 13G ownership disclosure

Trevi Therapeutics Inc

Common Stock · CUSIP: 89532M101

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Frazier Life Sciences Public Fund, L.P.

    Shares: 8,819,620.00 · Class: 9.9%

  • FHMLSP, L.P.

    Shares: 8,819,620.00 · Class: 9.9%

  • FHMLSP, L.L.C.

    Shares: 8,819,620.00 · Class: 9.9%

  • Frazier Life Sciences X, L.P.

    Shares: 428,000.00 · Class: 0.5%

  • FHMLS X, L.P.

    Shares: 428,000.00 · Class: 0.5%

  • FHMLS X, L.L.C.

    Shares: 428,000.00 · Class: 0.5%

  • Frazier Life Sciences XI, L.P.

    Shares: 1,417,154.00 · Class: 1.6%

  • FHMLS XI, L.P.

    Shares: 1,417,154.00 · Class: 1.6%

  • FHMLS XI, L.L.C.

    Shares: 1,417,154.00 · Class: 1.6%

  • James N. Topper

    Shares: 10,664,774.00 · Class: 11.9%

  • Patrick J. Heron

    Shares: 10,664,774.00 · Class: 11.9%

  • Albert Cha

    Shares: 8,819,620.00 · Class: 9.9%

  • James Brush

    Shares: 8,819,620.00 · Class: 9.9%

  • Daniel Estes

    Shares: 1,417,154.00 · Class: 1.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-003984
Form type
SCHEDULE 13G/A
Filer
Frazier Life Sciences Public Fund, L.P.
CIK
CIK 1863769
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub